Advicenne's Financial Calendar and Product Development

Advicenne, a pharmaceutical company, has announced its financial communication calendar for 2024, focusing on the development and commercialization of treatments for rare renal diseases. Its primary product, Sibnayal® (ADV7103), has received marketing authorization in Europe and the UK for the treatment of distal tubular renal acidosis (ATRd). The product is also in advanced clinical development for ATRd and cystinuria in Europe and the USA.